Familial breast cancer: What the radiologist needs to know;Familiäre brustkrebserkrankung: Klinische grundlagen und früherkennung

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 178, Issue 7, 2006, Pages 680-687

  Kühl, Christiane K ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Breast; Breast radiography; Diagnostic radiology; Mammography; MR imaging; Screening

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER GRADING; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ECHOGRAPHY; FAMILIAL CANCER; FIBROADENOMA; GENE MUTATION; GENETIC SUSCEPTIBILITY; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INHERITANCE; MAMMOGRAPHY; ONCOGENE; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOLOGIST; REVIEW;

BREAST NEOPLASMS; DIAGNOSTIC IMAGING; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MASS SCREENING; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; RADIOLOGY; RISK ASSESSMENT; RISK FACTORS;

EID: 33746927127     PISSN: 14389029     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-926749     Document Type: Review

References (41)

1. Miki Y, Swensen J, Shattuck-Eidens D et al. A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1. Science 1994; 266: 66-71
2. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792
3. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130
4. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 277: 997-1003
5. Ford D, Easton DF, Bishop DT et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-695
6. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689
7. Hamann U, Sinn HP. Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res Treat 2000; 59: 185-192
8. Hoskins KF, Stopfer JE, Calzone KA et al. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA 1995; 273: 577-585
9. Marcus JN, Watson P, Page DL et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996; 77: 697-709
10. Metcalfe K, Lynch HT, Ghadirian P et al. Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. J Clin Oncol 2004; 22: 2328-2335
11. Alpert TE, Haffty BG. Conservative management of breast cancer in BRCA1/2 mutation carriers. Clin Breast Cancer 2004; 5: 37-42
12. Kirova YM, Stoppa-Lyonnet D, Savignoni A et al for the Institut Curie Breast Cancer Study Group. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005; 41: 2304-2311
13. Moller P, Borg A, Evans DG et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 2002; 101: 555-559
14. Robson M, Gilewski T, Haas B et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998; 16: 1642-1649
15. Robson M, Levin D, Federici M et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 1999; 91: 2112-2117
16. Veronesi A, de Giacomi C, Magri MD et al. Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer 2005; 5: 70
17. Schmutzler R, Schlegelberger B, Meindl A et al. Kpnsortium Familiärer Brust- und Eierstockkrebs, Deutsche Krebshilfe. Beratung, Genetische Testung und Prävention von Frauen mit einer familiären Belastung für das Mamma- und Ovarialkarzinom. Interdisziplinäre Empfehlungen des Konsortiums "Familiärer Brust- und Eierstockkrebs" der Deutschen Krebshilfe. Zentralbl Gynakol 2003; 125: 494-506
18. Meijers-Heijboer H, van Geel B, van Putten WL et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-64
19. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062
20. Vasen HF, Haites NE, Evans DG et al. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur J Cancer 1998; 34: 1922-1926
21. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-1615
22. Olopade OI, Artioli G. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 2004; 10: 5-9
23. Pichert G, Bolliger B, Buser K et al. Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol 2003; 14: 9-19
24. Kuhl CK, Schmutzler RK, Leutner CC et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000; 215: 267-279
25. Kuhl CK, Schrading S, Weigel S et al. Die "EVA-Studie": Evaluierung der . Leistungsfähigkeit diagnostischer Verfahren (Mammographie, Sonographie, MRT) zur sekundären und tertiären Prävention des familiären Mammakarzinoms - Zwischenergebnisse nach der ersten Hälfte der Förderungsperiode. Fortschr Röntgenstr 2005; 177: 818-827
26. Brekelmans CT, Seynaeve C, Bartels CC et al. Rotterdam Committee for Medical and Genetic Counseling. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001; 19: 924-930
27. Kriege M, Brekelmans CT, Boetes C et al. Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-437
28. Kuhl CK, Schrading S, Leutner CC et al. Mammography, Breast Ultrasound and Magnetic Resonance Imaging for Surveillance of Women at High Familial Risk for Breast Cancer. J Clin Oncol 2005; 23: 8469-8476
29. Leach MO, Boggis CR, Dixon AK et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-1678
30. Podo F, Sardanelli F, Canese R et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 2002; 21 (3 Suppl): 115-124
31. Stoutjesdijk MJ, Boetes C, Jager GJ et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93: 1095-1102
32. Tilanus-Linthorst M, Verhoog L, Obdeijn IM et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 2002; 102: 91-95
33. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC et al. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000; 63: 53-60
34. Trecate G, Vergnaghi D, Bergonzi S et al. Breast MRI screening in patients with increased familial and/or genetic risk for breast cancer: a preliminary experience. Tumori 2003; 89: 125-131
35. Warner E, Plewes DB, Shumak RS et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001; 19: 3524-3531
36. Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317
37. Westerhof JP, Fischer U, Moritz JD et al. MR imaging of mammographically detected clustered microcalcifications: is there any value? Radiology 1998; 207: 675-681
38. Hwang ES, Kinkel K, Esserman LJ et al. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol 2003; 10: 381-388
39. Ikeda O, Nishimura R, Miyayama H et al. Magnetic resonance evaluation of the presence of an extensive intraductal component in breast cancer. Acta Radiol 2004; 45: 721-725
40. Van Goethem M, Schelfout K, Kersschot E et al. Enhancing area surrounding breast carcinoma on MR mammography: comparison with pathological examination. Eur Radiol 2004; 14: 1363-1370
41. Foulkes WD, Metcalfe K, Hanna W et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 2003; 98: 1569-1577